125 related articles for article (PubMed ID: 36460134)
1. Serum testosterone measured by liquid chromatography-tandem mass spectrometry is an independent predictor of response to castration in metastatic hormone-sensitive prostate cancer.
van Winden LJ; Lanfermeijer M; Dezentje V; Bergman AM; van der Poel HG; van Rossum HH
Clin Chim Acta; 2023 Jan; 539():34-40. PubMed ID: 36460134
[TBL] [Abstract][Full Text] [Related]
2. Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.
van der Sluis TM; Bui HN; Meuleman EJ; Heijboer AC; Hartman JF; van Adrichem N; Boevé E; de Ronde W; van Moorselaar RJ; Vis AN
J Urol; 2012 May; 187(5):1601-6. PubMed ID: 22425112
[TBL] [Abstract][Full Text] [Related]
3. Testosterone analysis in castrated prostate cancer patients: suitability of the castration cut-off and analytical accuracy of the present-day clinical immunoassays.
van Winden LJ; Lentjes EGWM; Demir AY; Huijgen HJ; Bergman AM; van der Poel HG; van Rossum HH
Clin Chem Lab Med; 2022 Sep; 60(10):1661-1668. PubMed ID: 35918785
[TBL] [Abstract][Full Text] [Related]
4. Serum Testosterone Levels in Prostate Cancer Patients Undergoing Luteinizing Hormone-Releasing Hormone Agonist Therapy.
Morote J; Comas I; Planas J; Maldonado X; Celma A; Placer J; Ferrer R; Carles J; Regis L
Clin Genitourin Cancer; 2018 Apr; 16(2):e491-e496. PubMed ID: 29198640
[TBL] [Abstract][Full Text] [Related]
5. Comparison of docetaxel pharmacokinetics between castration-resistant and hormone-sensitive metastatic prostate cancer patients.
Vermunt MAC; van Nuland M; van der Heijden LT; Rosing H; Beijnen JH; Bergman AM
Cancer Chemother Pharmacol; 2022 Jun; 89(6):785-793. PubMed ID: 35467095
[TBL] [Abstract][Full Text] [Related]
6. [Change of the LHRH analogue in progressive castration-refractory prostate cancer].
Heidenreich A; Porres D; Epplen R; van Erps T; Pfister D
Urologe A; 2012 Sep; 51(9):1282-7. PubMed ID: 22733398
[TBL] [Abstract][Full Text] [Related]
7. Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients.
Morote J; Comas I; Ferrer R; Planas J; Celma A; Regis L
J Biomed Sci; 2017 Oct; 24(1):81. PubMed ID: 29058606
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of low testosterone concentrations during and prior to enzalutamide treatment in metastatic castration-resistant prostate cancer.
van Winden LJ; Lanfermeijer M; Dezentje V; Bergman AM; van der Poel HG; van Rossum HH
Urol Oncol; 2023 Feb; 41(2):104.e11-104.e17. PubMed ID: 36379811
[TBL] [Abstract][Full Text] [Related]
9. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
[TBL] [Abstract][Full Text] [Related]
11. Monitoring urinary testosterone and epitestosterone levels, and their ratio, in Korean chemical castration subjects using liquid chromatography-tandem mass spectrometry.
Sim J; Cho B; Park M; Rhee J; In S; Choe S
J Anal Toxicol; 2020 Mar; 44(2):192-199. PubMed ID: 31322674
[TBL] [Abstract][Full Text] [Related]
12. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
Bryce AH; Chen YH; Liu G; Carducci MA; Jarrard DM; Garcia JA; Dreicer R; Hussain M; Eisenberger MA; Plimack ER; Vogelzang NJ; DiPaola RS; Harshman L; Sweeney CJ
Eur Urol Oncol; 2020 Dec; 3(6):717-724. PubMed ID: 32807727
[TBL] [Abstract][Full Text] [Related]
13. Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.
van der Sluis TM; van Moorselaar RJ; Meuleman EJ; ter Haar RW; Bui HN; Heijboer AC; Vis AN
Urology; 2013 May; 81(5):1005-9. PubMed ID: 23465153
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of methods for quantifying serum testosterone in patients with prostate cancer who underwent castration.
Comas I; Ferrer R; Planas J; Celma A; Regis L; Morote J
Actas Urol Esp (Engl Ed); 2018 Mar; 42(2):86-93. PubMed ID: 28259362
[TBL] [Abstract][Full Text] [Related]
15. Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.
Krakowsky Y; Morgentaler A
Eur Urol Focus; 2019 Jan; 5(1):81-89. PubMed ID: 28753828
[TBL] [Abstract][Full Text] [Related]
16. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
17. Retrospective analysis of serum testosterone levels by LC-MS/MS in chemically castrated prostate cancer patients: Biological variation and analytical performance specifications.
van Winden LJ; Lanfermeijer M; Heijboer AC; van Tellingen O; Bergman AM; van der Poel HG; Jonker N; van Rossum HH
Clin Chim Acta; 2021 Oct; 521():70-75. PubMed ID: 34217697
[TBL] [Abstract][Full Text] [Related]
18. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
19. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
20. Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?
Pickles T; Hamm J; Morris WJ; Schreiber WE; Tyldesley S
BJU Int; 2012 Dec; 110(11 Pt B):E500-7. PubMed ID: 22564197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
